Ovarian cancer is a relatively rare cancer, but the second most common gynecological cancer. It starts in the ovaries, the nearby fallopian tubes, or tissue called the peritoneum that covers the ...

Researchers at the University of Pittsburgh have identified a novel trigger of a deadly form of ovarian cancer: a subset of ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

Scientists have uncovered a hidden driver of ovarian cancer—high-risk mesenchymal stem cells lurking in the fallopian tubes.

Ovarian cancer can affect anyone born with female reproductive organs including the ovaries and fallopian tubes. This includes women, transgender men and non-binary people. We don’t know what causes ...

Optimizing telehealth during public health emergencies to minimize in-person appointments puts less burden on patients and ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.